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The purpose of this study was to ascertain whether
abdominal compression with an inflatable abdominal band,
a device we developed, improved post-dialytic orthostatic
hypotension (OH) in hemodialysis (HD) patients. Twenty-five
chronic HD patients with intractable post-dialytic OH were
recruited. Post-HD changes in systolic blood pressure (DSBP)
in the supine and standing positions were compared in the
patients, measured with or without the use of the band.
The study showed DSBP after HD without the band was
significantly greater than that measured before HD
(36.1718.2 vs 13.1716.8 mm Hg; Po0.0001). DSBP after
HD with the band was reduced significantly in comparison
to DSBP after HD without the band (19.4721.2 vs
36.1718.2 mm Hg; Po0.002). Use of the band did not
cause an elevation in SBP in the supine position (149.0729.6
vs 155.4725.7 mm Hg); however, it did increase SBP upon
standing (129.6727.3 vs 117.2722.6 mm Hg; Po0.05). Eight
patients in whom an increase in SBP of 25 mm Hg or more
was achieved with the band were classified as responders.
Ejection fraction was significantly higher (76.4711.1 vs 61.97
13.6%; Po0.02) and atrial natriuretic peptide concentration
significantly lower (27.9722.0 vs 68.9747.5 pg/ml; Po0.02)
in responders than in non-responders. We conclude that the
abdominal band was effective for overcoming post-dialytic
OH, without elevating supine SBP in some patients.
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Unstable blood pressure (BP) is considered an important risk
factor for mortality of hemodialysis (HD) patients. Intradia-
lysis hypotension and orthostatic hypotension (OH) after
HD are significant and independent factors that affect
mortality in HD patients.1 Intradialysis hypotension and
OH are known to adversely affect daily living activities and
the quality of life of HD patients and can lead to syncope and
hip fracture in these patients.1–4 Many new drugs and dialysis
techniques to control intradialysis hypotension have been
developed,5–14 with all being administered during HD itself.
Pharmacological treatment, however, becomes problematic
once the HD session is finished. In addition, OH after HD is
often complicated by supine hypertension and is difficult to
treat pharmacologically. For example, whereas volume
expansion, vasoconstrictive drugs, erythropoietin, and in-
creasing the circulatory blood volume are effective for
elevating standing BP,15–20 their use may aggravate supine
hypertension, making it difficult to adjust the drug dosages.
Many studies have suggested that hypertension in HD
patients is a cause of mortality and a risk factor for
cardiovascular disease and stroke.21–24 Zager et al.25 described
a U-shaped association between post-dialytic BP and
mortality, with increased risk being associated with raised
systolic BP (SBP). It is therefore important to avoid elevating
supine SBP when treating post-dialytic OH and there is a
need to develop novel treatments with minimal side effects
with this objective in mind.
Abdominal compression has been shown to overcome OH
in patients with autonomic dysfunction without elevating
supine SBP.26 There is also evidence that the use of
abdominal compression to maintain perfusion in non-
heart-beating liver donors also provided good long-term
results.27 We reported previously that abdominal compres-
sion using an inflatable abdominal band we developed,
reduced orthostatic hypotensive symptoms and BP decreases
in both diabetes patients and children with orthostatic
intolerance.28,29 We demonstrated that the abdominal band
shifted the blood pool from the abdominal vascular bed to
the thoracic space by reducing the volume of the abdominal
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vascular bed, thereby elevating central venous pressure and
preload needed to maintain cardiac output. The abdominal
band has also been reported to improve hypotensive
symptoms and cerebral blood flow in patients with ortho-
static intolerance.30–32
We hypothesized that the inflatable abdominal band may
also improve OH that often occurs after HD. To test this
hypothesis, HD patients with a history of OH after HD
participated in an active standing test, before and after HD,
with and without the use of an abdominal band.
RESULTS
Characteristics of the patients
The clinical backgrounds of the patients are summarized in
Table 1. The mean values in the study group were: age
68.3710.9 years; body weight after HD 59.2713.1 kg;
height 162.278.6 cm; duration of HD 52.8736.6 months;
HD time 4.070.3 h; ultrafiltration volume 2.370.9 kg;
cardiothoracic ratio after HD 49.074.0%; and hemato-
crit after HD 30.872.5%. The primary diseases necessita-
ting HD were diabetic nephropathy (n¼ 12, 48.0%),
chronic glomerulonephritis (n¼ 11, 44.0%), polycystic
kidney disease (n¼ 1, 4.0%), and kidney disease associated
with gout (n¼ 1, 4.0%). Cardiovascular disease was a
significant complicating factor in four patients (numbers 8,
9, 12, and 15). Antihypotensive medications administered
included L-threo-3,4-dihydroxyphenylserine in patients 1,
10, 17, 20, and 25, midodrine in patients 7, 8, and 22,
and amezinium metilsulfate in patients 4, 6, 11, and 16.
All patients were administrated recombinant human
erythropoietin.
Comparison of DSBP before HD and after HD with and
without the band
The results of the active standing tests are shown in Table 2.
DSBP was significantly greater after HD without the band
than before HD (36.2718.0 vs 13.1716.8 mm Hg;
Po0.0001). DSBP after HD was significantly less with the
band than without the band (36.2718.0 vs 19.47
21.2 mm Hg; Po0.002) (Table 2, Figure 1). To confirm the
efficacy of the abdominal band, we repeated the active
standing test with the abdominal band removed in some
patients (patients 1–8). DSBP with the band removed was
significantly greater than after HD with the band attached
(29.1711.3 vs 19.4721.2 mm Hg; P¼ 0.018) (Table 2).
This indicated that the reduction in SBP caused by standing
was attenuated by the band.
Use of the abdominal band did not lead to elevation
of SBP after HD measured in the supine position (SBP
without the band 153.4725.3 mm Hg vs SBP with the
band 149.0729.6 mm Hg, difference not significant). How-
ever, use of the abdominal band led to an elevation
in SBP after HD measured in the standing position
(SBP without the band 117.2722.6 mm Hg vs SBP
with the band 129.6727.3 mm Hg; Po0.05) (Table 2,
Figure 2).
Comparison of differences in heart rate after HD with and
without the band
Differences in heart rate (DHR) after HD was significantly
greater with the band than without the band (DHR with
the band 8.677.2 beats/min vs DHR without the band
2.078.3 beats/min; Po0.03) (Figure 2).
Frequency of OH and hypotensive symptoms before HD and
after HD with and without the band
Hypotensive symptoms were found in two of the 25 (8.0%)
patients before HD. Without use of the abdominal band after
HD, the number of patients with hypotensive symptoms
increased to 20 (80.0%). In contrast, when the abdominal
band was worn, the number of patients with hypotensive
symptoms decreased to 14 (56.0%) (Table 2). Two patients
had one hypotensive symptom before HD. Without the band
attached, 11 patients had one hypotensive symptom after
HD, eight patients had two symptoms, and one patient had
three symptoms. With the band attached, eight patients had
reduction in the number of hypotensive symptoms (Table 2).
Use of the band was therefore associated with a trend of
reduced hypotensive symptoms, although this change was
not statistically significant (without band 80.0% vs with band
vs 56.0%; P¼ 0.066).
Frequency of post-dialytic OH patients with supine
hypertension
Supine hypertension, defined as a SBP of 140 mm Hg or
higher before HD, was found in 21 of the 25 patients
(84.0%). After HD, 17 of the 25 (58.0%) patients with post-
dialytic OH had supine hypertension (Table 2).
Clinical background of patients who responded to the
abdominal band
The improvement in DSBP was bimodal with the boundary
between the two peaks being 20–25 mm Hg (Figure 3). We
tentatively categorized patients as responders if their
improvement in DSBP after HD with the band was 25 mm
Hg or more, compared to values measured without the band
(patients 1–8). The remaining patients were classified as non-
responders (patients 9–25) (Table 3). Ejection fraction (EF)
was significantly higher in the responders than in the non-
responders (76.4711.1 vs 61.9713.6%; P¼ 0.014), but there
was no significant difference in early diastolic velocity/atrial
contraction velocity (E/A) or muscle weight of the left
ventricle between the two groups. Atrial natriuretic peptide
(ANP) after HD was significantly lower in the responders
than in the non-responders (27.9722.0 vs 68.9747.5 pg/ml;
P¼ 0.018). There was no significant difference between the
two groups in average age, body weight, HD duration, HD
time, ultrafiltration volume, lowest SBP during HD, body
mass index, use of antihypotensive drugs, and presence of
diabetes mellitus. In addition, no significant difference was
observed in hematocrit, blood urea nitrogen, plasma glucose,
sodium, creatinine, total protein, albumin, triglyceride, total
cholesterol, plasma renin activity, aldosterone, epinephrine,
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norepinephrine, dopamine, or coefficient of variation of the
RR interval after HD between the two groups.
DISCUSSION
The main finding in this study was that abdominal band
therapy resulted in a mean improvement of 16.7 mm Hg in
the reduction of SBP that developed upon standing in HD
patients with a history of OH. Midodrine, a selective
a-adrenergic agonist, is useful for treating OH and dialysis
hypotension.17 Administration of midodrine and cool
dialysis has been shown to reduce the decline in SBP upon
standing after HD by approximately 11–17 mm Hg.17,33,34
L-threo-3,4-dihydroxyphenylserine is also an effective treat-
ment for post-dialytic OH and reduces the drop in SBP by
10–15 mm Hg.3,6,9 The effect of the abdominal band on BP in
our study was comparable or even better than drug treatment
or conventional therapies such as L-threo-3,4-dihydroxy-
phenylserine and midodrine. As the abdominal venous bed
is the largest vascular bed in the body and contains a pool
of blood about three times that of the legs and hips,
inhibition of abdominal blood pooling leads to a marked
elevation in SBP.35
Although leg-crossing exercise is useful for minimizing
OH,36,37 there are a number of HD patients who have
difficulty standing up and crossing their legs due to
hypotensive symptoms. In the present study, 20 of the 25
patients were unable to continue standing immediately
after HD owing to hypotensive symptoms. However, the
inflatable abdominal band was easily attached and able
to be compressed with the patients in the supine position
and therefore has the advantage that it can be used in
patients who are unable to stand because of post-dialytic
OH.
It is noteworthy that the abdominal band did not elevate
SBP in the supine position. Therefore, use of the band not
only prevented a large drop in SBP upon standing and
reduced hypotensive symptoms, but also did not aggravate
supine SBP. These properties make it an effective and
advantageous method for preventing dialytic OH.
Our study also showed band therapy was effective in
patients who were already taking antihypotensive drugs. As
these treatments act in different ways on the splanchnic
circulation, combined use of an antihypotensive drug and
abdominal band therapy may be useful for treating OH after
HD. L-threo-3,4-dihydroxyphenylserine substitutes for nor-
epinephrine in the central nervous system and affects a
variety of peripheral organs.3 An inflatable band, on the other
hand, reduces the pooling of splanchnic blood directly
thereby increasing central venous pressure and facilitating
stroke volume and cardiac output leading to an improvement
in OH.28,29
Patients in whom OH improved with the band had
significantly better EFs and lower ANP concentrations than
patients in whom OH did not improve. This indicated that
stable systolic heart function is necessary for an optimal
response to band therapy. EF provides a good indicator of
cardiac contract function.38 The abdominal band elevated
central venous pressure and increased preload. In contrast,
Table 1 | Background clinical characteristics of the patients
Patient
Age
(years)
Sex
(M/F)
Need
for HD
BW before
HD (kg)
BW after
HD (kg)
Height
(cm)
HD-d
(months)
HD-t
(hours) UF-v (kg)
CTR after
HD (%)
Ht after
HD (%)
1 65 M CGN 56.3 54.3 153 8 3.0 2.0 44.0 32.0
2 67 M DM 60.4 58.0 165 34 4.5 2.4 46.0 29.6
3 56 M PK 64.9 62.8 160 19 4.0 2.1 46.5 33.9
4 77 M CGN 56.2 53.8 165 113 4.0 2.4 51.0 27.6
5 76 M DM 61.0 59.7 160 127 4.0 1.3 45.5 29.8
6 56 M CGN 63.2 60.0 165 35 4.0 3.2 49.0 32.5
7 55 M DM 60.9 59.0 167 13 4.0 1.9 43.5 30.0
8 71 M DM 85.8 82.0 169 39 4.0 3.8 55.5 26.5
9 60 M DM 75.0 71.9 173 30 4.5 3.1 47.0 31.1
10 55 M DM 91.1 87.5 167 42 4.0 3.6 46.0 29.0
11 81 M GK 65.3 63.8 160 35 4.0 1.5 52.5 32.7
12 67 F DM 59.9 56.7 165 42 4.0 3.2 55.5 31.1
13 76 M DM 57.1 55.2 169 88 4.0 1.9 50.0 29.8
14 79 F CGN 43.4 41.1 147 51 4.0 2.3 53.0 33.1
15 80 M CGN 49.8 47.8 158 38 4.0 2.0 45.0 25.2
16 70 M CGN 62.2 59.8 164 50 4.0 2.4 44.5 29.7
17 71 M CGN 72.0 70.7 171 55 4.0 1.3 56.0 28.7
18 84 F CGN 46.3 45.4 143 67 4.0 0.9 44.0 31.9
19 60 M CGN 65.6 61.9 167 167 4.5 3.7 51.0 29.6
20 81 F DM 35.8 34.0 148 29 4.0 1.8 54.0 35.9
21 46 M DM 85.6 81.5 170 71 4.0 4.1 48.0 32.3
22 55 M DM 50.5 48.8 163 41 4.0 1.7 47.5 30.6
23 85 F CGN 39.4 38.0 148 52 3.5 1.4 53.5 35.5
24 72 M CGN 60.5 59.5 176 33 3.5 1.0 47.5 31.5
25 62 M DM 69.3 66.8 162 40 4.0 2.5 48.5 30.7
Mean7s.d. 68.3710.9 — — 61.5713.7 59.2713.1 162.278.6 52.8736.6 4.070.3 2.370.9 49.074.0 30.872.5
BW, body weight; CGN, chronic glomerulonephritis; CTR, cardiothoracic ratio; DM, diabetic nephropathy; F, female; GK, gout kidney; HD, hemodialysis; HD-d, hemodialysis
duration; HD-t, hemodialysis time; Ht, hematocrit; M, male; PK, polycystic kidney; UF-v, ultra filtration volume.
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Table 2 | Comparison of changes in SBP and hypotensive symptoms
Patient
Supine SBP
before HD
Ortho
before HD
DSBP
before HD
Lowest SBP
during HD
Number of
hypotensive
symptoms
during HD
Supine SBP
after HD
band ()
Ortho SBP
after HD
band ()
DSBP after
HD band ()
1 140 128 12 112  152 124 28
2 185 168 17 168  160 110 50
3 150 158 8 118  144 106 38
4 160 124 36 130  168 108 60
5 140 120 20 108  150 120 30
6 186 202 16 154 ++ 180 140 40
7 180 132 48 144 ++ 200 130 70
8 160 164 4 132 ++ 122 100 22
9 190 166 24 148  154 112 42
10 154 140 14 160 + 180 160 20
11 196 180 16 124  176 148 28
12 200 178 22 120 ++ 132 102 30
13 148 140 8 152  150 134 16
14 192 190 2 140 +++ 152 120 32
15 166 138 28 130 + 208 162 46
16 148 138 10 122 + 124 90 34
17 126 106 20 124  130 112 18
18 142 140 2 126  168 148 20
19 120 120 0 114 + 122 108 16
20 160 130 30 132 + 152 136 16
21 194 190 4 124  124 78 46
22 190 180 10 142  150 94 56
23 100 108 8 114  118 88 30
24 160 112 48 144  188 100 88
25 110 118 8 104  130 100 30
Mean7s.d. 159.9728.1 146.8728.5 13.1716.8 131.4716.8 40.0% 153.4725.3 117.3722.6 36.2718.0
Patient
Supine SBP
after HD
band (+)
Ortho SBP
after HD
band (+)
DSBP after
HD band (+)
Number of hypotensive symptoms Supine SBP
after HD
removed
band
Ortho SBP
after HD
removed
band
DSBP after
HD removed
bandBefore HD
After HD
band ()
After HD
band (+)
1 144 144 0  ++  142 128 14
2 184 162 22  + + 176 148 28
3 132 128 4  +  140 110 30
4 126 104 22  ++ + 144 122 22
5 110 119 9    130 110 20
6 178 185 7  ++  178 147 36
7 184 166 18 + ++  186 135 51
8 125 156 31  ++  140 108 32
9 160 110 50  + + 180 ND ND
10 207 183 24  ++ + 190 ND ND
11 187 157 30   + 171 ND ND
12 138 108 30  + + 146 ND ND
13 154 140 14  + + 148 ND ND
14 148 118 30    161 ND ND
15 194 150 44  + + 180 ND ND
16 129 98 31  ++ ++ 138 ND ND
17 116 103 13  + + 102 ND ND
18 144 130 14  ++ ++ 152 ND ND
19 94 90 4  +  108 ND ND
20 136 131 5  +  143 ND ND
21 130 96 34  +++ +++ 148 ND ND
22 170 128 42    160 ND ND
23 116 102 14    128 ND ND
24 180 108 72 + + + 180 ND ND
25 138 124 14  + + 135 ND ND
Mean7s.d. 149.0729.6 129.6727.3 19.4721.2 8.0% 80.0% 56.0% 153.0724.5 126.0716.3
(n=8)
29.1711.3
(n=8)
HD, hemodialysis; ND, not determined; SBP, systolic blood pressure; DSBP, changes in systolic blood pressure.
Supine SBP before HD: SBP, in supine position before HD.
Ortho SBP before HD: SBP in orthostatic position before HD; DSBP: change in SBP from a supine position to a standing position; band (+/): DSBP with or without an
abdominal; removed band: after the band was removed band. All are shown as mm Hg. +: one hypotensive symptom; ++: two hypotensive symptoms; +++: three
hypotensive symptoms; : no symptoms.
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cardiac output with a low EF would not have increased owing
to abnormal contraction of the left ventricle.
ANP is a peptide hormone with diuretic and vasodilatory
effects that is secreted from the atrium in response to
stretching stimuli. In HD patients, in particular, ANP levels
have been shown to correlate with the diameter and volume
of the inferior vena cava and also with preload.39–41
Therefore, a pathogenic mechanism may exist in patients
with a high post-HD ANP concentration, whereby cardiac
output is not maintained upon standing, despite preload
being elevated before band therapy. Therefore, despite the
movement of blood into the thoracic space following
abdominal compression and further elevation of preload, it
is difficult to maintain BP in these patients owing to a poor
response mechanism. Taken together, these findings indicate
that stable cardiac function without increased preload is
necessary to achieve a good response to treatment with an
abdominal band.
In conclusion, use of an abdominal band appears to be
effective for preventing OH after HD without causing an
elevation in supine BP. Patients whose heart function remains
stable have a better BP response to the abdominal band.
MATERIALS AND METHODS
The subjects in the study were 25 consecutive outpatients at either
Sanko Hospital, Sanko Clinic, or Sanko Gunge Clinic, enrolled
consecutively during the period from July to August 2004, who had
developed OH immediately after HD sessions (three sessions per
week). Post-dialytic OH in these patients was defined as a drop in
SBP of 15 mm Hg or more upon standing, as well as hypotensive
symptoms soon after HD.19 All the patients had experienced post-
dialytic OH and hypotensive symptoms for at least 6 months before
the start of the study. The patients confirmed by means of a self-
report questionnaire that post-dialytic OH prevented them main-
taining a standing position after HD. The patients had previously
received treatment for OH, such as control of plasma volume during
HD, control of BP by vasopressors, and administration of either
antihypotensive drugs, agents that increased circulatory volume or
recombinant human erythropoietin. The study was approved by the
ethics committee of Sanko Hospital, Sanko Clinic, and Sanko Gunge
Clinic. A detailed explanation of the study protocol was given to the
subjects before them giving written, informed consent, according to
the Declaration of Helsinki Principles.42
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Figure 1 | Comparison of DSBP before and after HD with and
without use of the abdominal band. DSBP: change in SBP from the
supine position to the standing position; HD: hemodialysis. Statistical
analysis of data from paired samples was performed by the Wilcoxon
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Figure 2 | Comparison of SBP and HR in the supine and standing
positions, measured before and after HD, with and without use
of the abdominal band. Statistical analysis of paired samples was
carried out using the Wilcoxon signed-rank test (*Po0.001,
**Po0.0001). Unpaired samples were analyzed by the Mann–Whitney
U-test (wPo0.05). All measurements are expressed as mean7s.d.
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Figure 3 | The improvement in decline of SBP upon standing with
use of the band. The improvement in DSBP was defined as the
difference between DSBP after HD with and without the band.
The cutoff point used to classify the patients as responders or
non-responders was set at 20–25 mm Hg and represented the
boundary in the bimodal distribution.
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Table 3 | Clinical details of the patients grouped according to responders or non-responders to the abdominal band
Patient Alb (mg/dl) PG (mg/dl) BUN (mg/dl) Na (mEq/l) CVRR (%) Epi (pg/ml) NEpi (pg/ml)
1 3.6 122 66 140 2.08 5 340
2 4.1 117 68 138 0.28 57 603
3 3.9 73 85 142 8.80 7 130
4 4.0 112 82 141 1.61 13 371
5 3.8 169 90 140 PVCs 28 480
6 4.2 86 86 136 2.26 40 452
7 3.6 255 60 139 1.17 5 50
8 3.6 183 49 138 1.10 12 566
9 3.9 201 88 141 2.52 50 354
10 2.9 182 91 141 0.31 34 240
11 3.5 104 60 143 0.36 6 152
12 4.1 97 84 139 3.12 18 298
13 3.9 183 72 143 PVCs 13 143
14 3.7 138 55 141 PVCs 20 179
15 3.6 206 48 139 0.47 6 66
16 4.0 181 59 134 PVCs 22 1075
17 3.9 154 56 142 0.81 34 547
18 3.5 98 73 142 1.28 13 286
19 3.5 115 104 142 4.92 11 306
20 3.4 198 71 139 PVCs 38 400
21 4.2 233 71 139 6.51 32 449
22 3.6 156 28 139 PVCs 26 201
23 4.1 112 87 138 PVCs 76 374
24 3.3 120 72 142 9.14 82 67
25 4.4 147 76 136 1.41 18 255
Mean7s.d.
Responder (1–8) 3.970.2 139.6759.7 73.3714.6 139.371.9 1.3470.42 20.9719.1 374.07197.2
Non-responder (9–25) 3.770.4 154.4742.6 70.3718.3 140.072.5 3.4073.35 29.4722.2 317.27234.9
Patient Dop (pg/ml) Ald (mEq/l) PRA (ng/ml/h) hANP (pg/ml) EF (%) E/A (mm/sec) MWLV (g)
1 8 41 45.0 20 0.74 1.11 205.2
2 17 180 180.0 16 0.89 2.17 162.6
3 5 110 4.6 24 0.73 0.78 355.1
4 12 43 43.0 80 0.65 2.43 297.4
5 18 74 12.0 11 0.86 2.36 257.4
6 21 190 130.0 16 0.87 0.94 323.2
7 44 27 2.8 25 0.79 1.34 291.9
8 18 57 14.0 31 0.58 1.89 556.5
9 10 300 24.0 10 0.58 1.96 268.6
10 16 68 68.0 44 0.78 1.72 297.5
11 5 75 4.5 58 0.71 1.41 316.5
12 32 95 23.0 170 0.44 SF 649.9
13 10 45 2.0 120 0.69 1.61 348.1
14 8 56 2.8 63 0.71 0.89 198.0
15 5 33 7.0 110 0.53 1.00 325.2
16 44 67 220.0 13 0.86 1.80 327.9
17 63 34 2.0 51 0.46 1.10 367.5
18 10 25 2.3 39 0.74 1.39 189.3
19 17 54 2.9 24 0.63 1.15 287.3
20 9 320 28.0 33 0.72 1.50 226.8
21 27 77 8.0 73 0.60 SF 364.9
22 36 32 63.0 130 0.65 1.64 248.4
23 19 68 2.7 47 0.40 SF 252.1
24 28 31 2.0 140 0.63 1.87 303.0
25 11 190 41.0 47 0.40 0.45 234.8
Mean7s.d.
Responder (1–8) 17.9711.9 90.3760.7 53.9766.0 27.9722.0* 0.7670.11* 1.6370.66 306.27118.8
Non-responder (9–25) 20.6716.0 92.4790.4 29.6753.5 68.9747.5* 0.6270.12* 1.4070.43 306.27104.0
Alb, albumin; Ald, aldsterone; BUN, blood urea nitrogen; CVRR: coefficient of RR intervals; Dop, dopamine; E/A, E wave/A wave; EF, ejection fraction; Epi, epinephrine; hANP,
human atrium natriuretic peptide; MWLV, muscle weight of left ventricle; NEpi, norepinephrine; PG, plasma glucose; PRA, plasma renin activity; PVCs, premature ventricle
contractions; SF, single flow.
Responders vs non-responders: *P=0.018; **P=0.014 by Mann–Whitney U-test.
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The patients comprised 20 men and five women. Hollow fiber
membranes were used for HD with the temperature of the HD fluid
being controlled between 35.8 and 36.21C. The rate of ultrafiltration
was set at a nominal average rate of 500 ml/min (440–540 ml/min)
and changed at appropriate times when SBP dropped by 30 mm Hg
or more or when hypotensive symptoms developed during HD.
Sodium concentration in the dialysis bath was 138 mEq/l. The
patients did not eat during HD. Antihypotensive drugs were not
administered during the study. Exclusion criteria were severe anemia
(hematocrit o25.0%), a bleeding tendency, hypervolemic symp-
toms such as leg edema and pleural effusion, poor compliance,
treatment for apparent infection, and a need for admission to the
hospital. Patients with chronic hypotension, defined as a pre-dialysis
SBP of 100 mm Hg or lower were also excluded.
Measurement of changes in SBP and HR upon standing
The magnitude of the fall in SBP upon standing after HD is regarded
as a significant determinant of mortality.1 Iida et al.19 revealed that
post-dialytic OH appeared within 1 min of standing following HD.
We therefore measured SBP and HR after the patient had stood for
1 min after rising from the supine position. This was called the
active standing test and was carried out beside the dialysis bed.
The differences in SBP and HR measured in the supine and
standing positions before HD, were defined as DSBP before HD and
DHR before HD, respectively. The presence of hypotensive
symptoms after standing such as fatigability, malaise and weakness,
dizziness, cramps, and lightheadedness, was documented using self-
reported questionnaires.
After HD was finished and the extracorporeal circulation had
been closed, the patients were asked to rest in the supine position for
15 min. When a stable BP was confirmed, the patients undertook an
active standing test, either with or without the abdominal band. The
differences in SBP and HR between the supine and standing
positions were defined as DSBP after HD without the band and
DHR after HD without the band, respectively. The prevalence of the
specified hypotensive symptoms that developed after standing was
also recorded in the self-reported questionnaires.
After a further 15 min of rest in the supine position, an inflatable
abdominal band was placed around the patient’s body28,29 and
centered over the umbilicus. The air bag was then inflated to 20 mm
Hg pressure and stabilization of BP confirmed after 15 min of rest in
the supine position. The inflatable abdominal band consisted of an
inner and outer band and was sufficiently flexible to compress the
abdominal wall. The outer band was 21 cm in width and made of
synthetic fibers with elasticity similar to breast bands, whereas the
inner band was equipped with a controllable airbag (20 25 cm2)
positioned, so that it compressed the abdominal wall. The airbag
was pressurized by an inflator, with the inner pressure being
monitored by a small aneroid type BP monitor.30
The patients were then asked to stand, followed by measurement
of SBP 1 min later. Differences in SBP and HR between the supine
and standing positions were defined as DSBP after HD with the
band and DHR after HD with the band, respectively, whereas the
presence of the specified hypotensive symptoms after standing was
recorded in the self-reported questionnaires.
Other clinical investigations in the study
During the study, we examined factors that may contribute to post-
dialytic OH. Blood was collected from the shunt at the end of HD
for the measurement of hematocrit, blood urea nitrogen, plasma
glucose, sodium, creatinine, total protein, albumin, triglyceride,
total cholesterol, plasma renin activity, aldosterone, epinephrine,
norepinephrine, dopamine, and human ANP. Epinephrine, norepi-
nephrine, and dopamine were measured by a high-pressure liquid
chromatography method, whereas plasma renin activity was
measured by radioimmunoassay.
After 15 min of rest in the supine position following HD, an
electrocardiogram (Fukuda Denshi Ltd, Tokyo, Japan) was obtained.
The RR interval was measured, and the coefficient of variation of the
RR interval calculated. A chest X-ray film was obtained after HD in
order to measure the cardiothoracic ratio.
Ultrasonographic cardiography (SSD-5000, Aloka Co. Ltd,
Tokyo, Japan) was performed after HD to evaluate fractional
shortening and EF. Using Doppler echocardiography, we also
measured transmitral peak early diastolic velocity (E), transmitral
peak atrial contraction velocity (A), and the ratio of these two
variables (E/A). The muscle weight of the left ventricle (MWLV) was
measured according to the following equation:
MWLV ¼ 1:04ðLVDd þ IVST þ LVPWTÞ3  1:04LVDd3  13:6
where LVDd¼ left ventricular diastolic diameter; IVST¼ internal
ventricular segmental thickness; and LVPWT¼ left ventricular
posterior wall thickness.
Statistical analysis
The data were expressed as mean7s.d. Paired samples were analyzed
by the Wilcoxon signed-rank test, whereas non-paired data were
analyzed by the Mann–Whitney U-test. All analyses were performed
with StatView, version 5.0 (SAS Inc., Cary, NC, USA). A P-value of
less than 0.05 was considered as statistically significant.
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